25-Hydroxycholesterol inhibits Hantavirus infection by reprogramming cholesterol metabolism
Yamei Dang,Yuan Wang,Jing Wei,Hui Zhang,Qiqi Yang,Bin Wang,Jia Li,Chuantao Ye,Yang Chen,Peijun Han,Xiaolei Jin,Jia Wang,Xiaohui Bao,He Liu,Hongwei Ma,Liang Zhang,Linfeng Cheng,Yangchao Dong,Yinlan Bai,Yinghui Li,Yingfeng Lei,Zhikai Xu,Fanglin Zhang,Wei Ye
DOI: https://doi.org/10.1016/j.freeradbiomed.2024.08.029
2024-08-28
Abstract:Hantavirus causes two types of acute diseases: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. It is a major health concern due to its high mortality and lack of effective treatment. Type I interferon treatment has been suggested to be effective against hantavirus when treated in advance. Interferons induce multiple interferon-stimulated genes (ISGs), whose products are highly effective at resisting and controlling viruses. A product of ISGs, the enzyme cholesterol 25-hydroxylase (CH25H), catalyzes the oxidation of cholesterol to 25-hydroxycholesterol (25HC). 25HC can inhibit multiple enveloped-virus infections, but the mechanism is largely unknown, and whether 25HC plays an important role in regulating hantavirus remains unexplored. In this study, we show that Hantaan virus (HTNV), the prototype hantavirus, induced CH25H gene in infected cells. Overexpression of CH25H and treatment with 25HC, inhibited HTNV infection, possibly by lowering 3-hydroxy-3-methyl-glutaryl coenzyme A reductase (HMG-CoA reductase, HMGCR), which inhibits cholesterol biosynthesis. In addition, cholesterol-lowering drugs such as HMGCR-targeting statins have potent hantavirus inhibitory effects. Our results indicate that 25HC and some statins are potential antiviral agents effective against hantavirus infections. This study provides evidence that targeting cholesterol metabolism is promising in developing specific hantavirus antivirals and indicates the possibility of repurposing FDA-approved cholesterol-lowering drug, statins for treating hantavirus infection.